Early treatment with AL-S Pharma‘s infusion therapy AP-101 significantly extended survival and delayed the need for respiratory support in people with amyotrophic lateral sclerosis (ALS), compared with a six-month delay in starting therapy, new trial data show. The therapy candidate is being developed to target and clear…